- Description:
-
The LUMC has purchased the NanoString Platform (nCounter MAX). The purchase was not announced in advance. The LUMC uses the tender procedure: Negotiation without prior notice. The reason for this procedure is:
The NanoString platform is a bench top machine capable of extended multiplexed hybridization reactions of nucleotides.
It quantifies up to 800 different RNA or DNA molecules from a single sample. It has build in analysis software
The NanoString technique must be positioned between qPCR and Next Gen sequencing and is ideal to perform pathway-based systems biology.
Advantages:
· Extended multiplex with quantification of 800 genes with small sample sizes (100 ng of RNA), like tumour biopsies.
ð mRNA, microRNA as well as long-non coding RNA; Single cell RNA analysis also possible with limited amplification ; Also Paraffin embedded sample analysis
· Copy number variation (CNV) analysis of DNA, CHIP-seq analysis and chromosomal translocations.
· Protein expression analysis also possible, currently up to 30 different proteins.
· Ready-to-use purchasable cartridges with selected set of genes (panCancer gene set for oncology, immunology gene set, inflammatory disease gene set) for mouse and man. Possibility to add own set of 30 genes.
· Also be used for analysis of the complex tumor microenvironment, changes in blood, lymph nodes and spleen in mouse models for the immunotherapy of cancer.
If parties have objections against the purchase from NanoString, please inform LUMC. by sending an email directed at: aanbestedingen@lumc.nl with reference to Mr. D. Bauw, Procurement.
- Documents:
-
- Type:
- Unsealed
|